Low HDL cholesterol the biggest modifiable risk for cardiovascular disease in patients with HIV (updated)

This article is more than 13 years old. Click here for more recent articles on this topic

Low HDL cholesterol is a bigger risk factor for cardiovascular disease in HIV-positive patients than smoking, total cholesterol, blood pressure or sex, Irish investigators report in the online edition of AIDS.

The researchers found that low HDL (high-density lipoprotein) cholesterol was second only to age as a risk factor for cardiovascular disease (CVD).

“Our data highlight the important contribution of low HDL-c to CVD [risk in HIV-infected patients,” comment the investigators.

Glossary

cholesterol

A waxy substance, mostly made by the body and used to produce steroid hormones. High levels can be associated with atherosclerosis. There are two main types of cholesterol: low-density lipoprotein (LDL) or ‘bad’ cholesterol (which may put people at risk for heart disease and other serious conditions), and high-density lipoprotein (HDL) or ‘good’ cholesterol (which helps get rid of LDL).

cardiovascular

Relating to the heart and blood vessels.

cardiovascular disease

Disease of the heart or blood vessels, such as heart attack (myocardial infarction) and stroke.

referral

A healthcare professional’s recommendation that a person sees another medical specialist or service.

lipoprotein

Any member of a group of substances containing both lipid (fat) and protein. Lipoproteins are found in both blood plasma and cell membranes. They are the mode of transport for cholesterol through the bloodstream and lymphatic fluid. 

HDL cholesterol is often referred to as “healthy cholesterol” and adequate amounts of it have long been associated with a lower risk of cardiovascular disease and other illnesses.

There is a high prevalence of low HDL cholesterol in patients with HIV. The reasons are unclear, but could include the effects of HIV, or the side-effects of some antiretroviral drugs.

Investigators at the Mater Misericordiae University Hospital in Dublin wished to determine the contribution of low HDL-cholesterol to cardiovascular risk in their HIV-positive patients.

They therefore performed a cross-sectional study, monitoring HDL-cholesterol levels and other  established cardiovascular risks in 127 patients who received care at the hospital between 2008 and 2010.

The median age of the patients was 37, two-thirds were men, and 58% were white. The median CD4 cell count was 378 cells/mm3 and 65% of patients were taking antiretroviral therapy, with 83% of these individuals having an undetectable viral load.

Many of the patients had well-known risk factors for cardiovascular disease. Over a third (38%) were smokers, 20% had a family history of cardiovascular disease, and 11% had high blood pressure.

Cholesterol monitoring showed that 3% of individuals had elevated total -cholesterol, 5% had high LDL (low density lipoprotein)-cholesterol - often referred to as “bad” cholesterol -  and 53% had low HDL-cholesterol.

Using the Framingham scale, 110 patients were assessed as having a low ten-year risk of cardiovascular disease, with twelve individuals having a moderate risk, and five a high risk.

The investigators calculated that the biggest single risk factor for cardiovascular disease in their patients was age. This accounted for 41% of the risk.

However, the next most important factor was low HDL cholesterol, which was responsible for 18% of the risk. This far exceeded the risk attributed to smoking (7%), total cholesterol (4%), and gender (2%).

Using a mathematical model, the researchers showed that boosting levels of HDL cholesterol had the potential to lead to health benefits..

An increase in HDL cholesterol levels by 20% would mean that five patients who were previously classified as having a moderate ten-year risk of cardiovascular disease were reclassified as having a low risk, and one patient was moved from the high to moderate risk group.

If HDL cholesterol levels were increased by between 20%-40% then twice as many patients had their risk downgraded.

The investigators calculated that this would have an impact on rates of cardiovascular disease: a 20% increase would mean 1.26 fewer cardiovascular events over ten years, and a 40% increase would prevent 2.41 events over a similar time period.

“In a cohort of HIV-infected patients HDL-c contributed more to CVD risk than smoking, total cholesterol, blood pressure and sex,” comment the investigators.

They acknowledge that a limitation of the study was its small sample size. However, they stress their cohort was “representative of a contemporary HIV-infected population.”

The investigators conclude “further research is warranted, in order to explain why HDL-c is low in HIV-infected patients and to identify potential therapeutic targets.”

References

Cotter AG et al. High-density lipoprotein levels and 10-year cardiovascular risk in HIV-infected patients. AIDS 25: online edition (DOI: 10.1097/QAD.ob013e3283450f0), 2011 (click here for the full text (£)).